Rafferty Asset Management
SUPN icon

Rafferty Asset Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Rafferty Asset Management’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-5,065
Closed -$252K – 1140
2025
Q4 		$252K Buy
5,065
+385
+8% +$18.7K ﹤0.01% 1031
2025
Q3 		$224K Buy
+4,680
New +$188K ﹤0.01% 1055
2024
Q4 		– Sell
-7,570
Closed -$236K – 1173
2024
Q3 		$236K Sell
7,570
-43
-0.6% -$1.34K ﹤0.01% 1072
2024
Q2 		$204K Buy
+7,613
New +$221K ﹤0.01% 1136
2022
Q1 		– Sell
-6,908
Closed -$201K – 1319
2021
Q4 		$201K Sell
6,908
-1,589
-19% -$48.2K ﹤0.01% 1228
2021
Q3 		$227K Buy
+8,497
New +$228K ﹤0.01% 1173
2019
Q4 		– Sell
-7,862
Closed -$216K – 902
2019
Q3 		$216K Buy
+7,862
New +$233K ﹤0.01% 773
2018
Q2 		– Sell
-56,529
Closed -$2.59M – 699
2018
Q1 		$2.59M Buy
+56,529
New +$2.36M 0.04% 228

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Rafferty Asset Management's SUPN Position: Q1 2026 in Review

Rafferty Asset Management sold out of Supernus Pharmaceuticals (SUPN) in Q1 2026, closing a stake of 5,065 shares — an estimated $252K sold.

Rafferty Asset Management first reported a position in SUPN in Q1 2018 and held it in 8 quarters. The position peaked at $2.59M in Q1 2018. 327 funds tracked by Wall St. Rank hold SUPN as of Q1 2026.

  • Rafferty Asset Management reported no remaining Supernus Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Rafferty Asset Management sold 5,065 Supernus Pharmaceuticals shares in Q1 2026, an estimated $252K.
  • Rafferty Asset Management first reported a position in Supernus Pharmaceuticals in Q1 2018 and held it in 8 quarters.
  • Rafferty Asset Management's Supernus Pharmaceuticals position peaked at $2.59M in Q1 2018.
  • 327 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2026.

Based on Rafferty Asset Management's 13F filing for Q1 2026, filed 15 May 2026.